Cytosine ß-D-Arabinofuranoside Drug Sensitivity in Down Syndrome Lymphoblastoid Cell Lines
Loading...
Authors
Bartnik, Catherine Michelle
Issue Date
2008
Type
Presentation
Language
en_US
Keywords
Alternative Title
Abstract
Down syndrome (DS) individuals have an increased risk of developing
acute myeloid leukemia (AML) at a young age. A remarkable feature of DS AML
is the high event free survival (EFS) rate in comparison to non-DS AML
individuals. It has been postulated that this positive prognosis is the result of a
high-dose protocol utilizing the chemotherapeutic agent, cytosine ß-Darabinofuranoside
(Ara-C). The sensitivity of DS and non-malignant non-DS
lymphoblastoid cells (LCLs) to Ara-C is not known and is an area of scientific
interest. This study compares sensitivity to Ara-C in LCLs derived from DS
individuals to those from individuals without DS. Analysis of the cohort (n= 124)
found DS LCLs to be significantly more sensitive to Ara-C at the 5 μM
concentration, and with respect to IC50 value and AUC value. These results
confirm the presence of a non-tumor genetic factor influencing drug sensitivity in
DS individuals. The factor, if found, could greatly change the treatment of non-DS
AML individuals
Description
Citation
Publisher
Kalamazoo, Mich. : Kalamazoo College.
License
U.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder.